Company Profile

MEKanistic Therapeutics LLC
Profile last edited on: 9/15/22

Novel cancer drugs to overcome resistance to targeted therapies
Year Founded
2015
First SBIR Year
2017
Latest SBIR Award
2021
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

U-M Venture Accelerator 1600 Huron Parkway:Huron Parkway
Ann Arbor, MI 48109
Multiple Locations:   
Congressional District:   12
County:   Washtenaw

Public Profile

With strong ties to University of Michigan, MEKanistic Therapeutics is a startup focused on the development of cancer therapeutics. Principals of the firm have discovered and designed small molecules that can selectively hit two cancer targets simultaneously with reduced risk of drug-drug interactions. Anchored in work pioneering the discovery and development of MEK inhibitors -- now in clinical use for the treatment of melanoma -- the computational chemistry expertise of one one the principals complements the cancer biology expertise of the other. The focus is on design of more effective drugs to circumvent resistance mechanisms commonly encountered with currently available kinase-targeted agents. The firm's lead compound, MTX-211, represents a first-in-class molecule that selectively and potently inhibits both of these critical oncogenic kinases, which are known to drive progression in a number of tumor types, including colorectal cancer. Currently, there are no approved treatments for patients diagnosed with metastatic KRAS mutant colorectal cancer. MTX-211 is innovative because it attacks KRAS oncogenic signaling using two independent mechanisms, serving effectively as a combination approach in a single molecule. Firm is listed as having raised $30M in June 2022 but not clear if monies actually allocated.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Judith Sebolt-Leopold -- Co-Founder

  Christopher Emil Whitehead -- Co-Founder

SBIR firms in the news